Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Ovid Therapeutics Inc.

Market Cap 422M 364M 335M 314M 590M 39.86B 596M 3.96B 1.55B 19.52B 1.58B 1.55B 67.55B P/E Ratio 2026 *
-4.68x
P/E Ratio 2027 * -4.24x
Enterprise Value 422M 364M 335M 314M 590M 39.86B 596M 3.96B 1.55B 19.52B 1.58B 1.55B 67.55B EV / Sales 2026 *
3,924x
EV / Sales 2027 * 2,531x
Free-Float
93.01%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ovid Therapeutics Inc.

1 day-1.74%
1 week-4.24%
Current month-17.22%
1 month-14.07%
3 months+14.72%
6 months+44.87%
Current year+38.65%
1 week 2.16
Extreme 2.162
2.5
1 month 2.16
Extreme 2.162
2.77
Current year 1.36
Extreme 1.36
3.1
1 year 0.29
Extreme 0.2851
3.1
3 years 0.24
Extreme 0.2425
4.14
5 years 0.24
Extreme 0.2425
4.5
10 years 0.24
Extreme 0.2425
15.93
Manager TitleAgeSince
Chief Executive Officer 45 01/01/2026
Director of Finance/CFO 56 02/06/2021
Chief Tech/Sci/R&D Officer 60 02/12/2025
Director TitleAgeSince
Chairman 72 01/04/2014
Director/Board Member 73 30/09/2015
Director/Board Member 81 23/11/2015
Date Insider Type Main position Quantity % Market Cap.
04-07Free

Director

17,578 0.0133%
04-07Free

Director

8,789 0.0067%
04-07Free

Director

17,578 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
-1.74%-4.24%+706.57%-36.87% 422M
-0.39%+0.03%+56.94%+107.84% 54.92B
-0.34%+3.51%+45.55%+40.16% 44.31B
+0.29%+6.20%-14.80%-19.65% 22.96B
-0.40%+3.49%-1.29%+387.06% 21.12B
-3.04%+0.07%+13.06%-36.86% 16.31B
-1.55%-2.39%+6.61%-41.28% 15.19B
-0.24%+2.44%+27.43%+177.49% 13.32B
+1.81%+10.22%+19.74% - 12.48B
+0.32%+2.81%+96.37%+213.49% 11.21B
Average -0.53%+2.06%+95.62%+87.93% 21.23B
Weighted average by Cap. -0.42%+2.84%+33.37%+94.81%

Financials

2026 *2027 *
Net sales 108K 92.65K 85.27K 80K 150K 10.16M 152K 1.01M 394K 4.98M 403K 395K 17.22M 167K 144K 132K 124K 233K 15.75M 235K 1.56M 611K 7.71M 625K 612K 26.69M
Net income -77.12M -66.47M -61.18M -57.39M -108M -7.29B -109M -723M -283M -3.57B -289M -283M -12.35B -89.84M -77.43M -71.26M -66.85M -126M -8.49B -127M -842M -329M -4.16B -337M -330M -14.39B
Net Debt - -
Logo Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Employees
23
Date Price Change Volume
15/06/26 2.260 $ -1.74% 1,843,325
12/06/26 2.300 $ +4.07% 2,061,967
11/06/26 2.210 $ -3.07% 2,883,375
10/06/26 2.280 $ -5.79% 1,607,475
09/06/26 2.420 $ +2.54% 1,483,639
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.260USD
Average target price
5.471USD
Spread / Average Target
+142.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!